Learning whether to subtract beta-blockers: it's about time

Learning whether to subtract beta-blockers: it's about time

Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2021-03, Vol.42 (9), p.915-918
Hauptverfasser: van Diepen, Sean, Armstrong, Paul W
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 918
container_issue 9
container_start_page 915
container_title European heart journal
container_volume 42
creator van Diepen, Sean
Armstrong, Paul W
description Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or post-infarction complications. The horizontal time axis proposes duration of therapies and timeframes for pharmacotherapeutic re-assessment, and should be responsive to the temporal evolution of post-MI risk and events. ADP, adenosine diphosphate receptor inhibitors; ASA, acetylsalicylic acid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trials; TG, triglyceride. *Pending guideline recommendations.
doi_str_mv 10.1093/eurheartj/ehaa1033
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2477261853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2477261853</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-779066f5f02c54522ebff7450c4308c6fc33445257a46cad35ca6e54a67d4c3a3</originalsourceid><addsrcrecordid>eNo9kEtLAzEUhYMotlb_gAvJTjdj886MrkrxBQU3Cu5CJr1xps50apJB_PeO9LG6cDnn4_AhdEnJLSUFn0IfKrAhraZQWUsJ50doTCVjWaGEPEZjQguZKZV_jNBZjCtCSK6oOkUjzgXLNcnH6H4xENb1-hP_VJAqCDh1OPZlCtYlXEKyWdl07gtCvMN1uo7Yll2fcKpbOEcn3jYRLnZ3gt4fH97mz9ni9ellPltkjgudMq0LopSXnjAnxTAPSu-1kMQJTnKnvBvmDH-prVDOLrl0VoEUVumlcNzyCbrZcjeh--4hJtPW0UHT2DV0fTRMaM0UzSUfomwbdaGLMYA3m1C3NvwaSsy_NHOQZvbShtLVjt-XLSwPlb0l_gcQimr7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2477261853</pqid></control><display><type>article</type><title>Learning whether to subtract beta-blockers: it's about time</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>van Diepen, Sean ; Armstrong, Paul W</creator><creatorcontrib>van Diepen, Sean ; Armstrong, Paul W</creatorcontrib><description>Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or post-infarction complications. The horizontal time axis proposes duration of therapies and timeframes for pharmacotherapeutic re-assessment, and should be responsive to the temporal evolution of post-MI risk and events. ADP, adenosine diphosphate receptor inhibitors; ASA, acetylsalicylic acid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trials; TG, triglyceride. *Pending guideline recommendations.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehaa1033</identifier><identifier>PMID: 33428708</identifier><language>eng</language><publisher>England</publisher><ispartof>European heart journal, 2021-03, Vol.42 (9), p.915-918</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-779066f5f02c54522ebff7450c4308c6fc33445257a46cad35ca6e54a67d4c3a3</citedby><cites>FETCH-LOGICAL-c347t-779066f5f02c54522ebff7450c4308c6fc33445257a46cad35ca6e54a67d4c3a3</cites><orcidid>0000-0002-0460-3445</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33428708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Diepen, Sean</creatorcontrib><creatorcontrib>Armstrong, Paul W</creatorcontrib><title>Learning whether to subtract beta-blockers: it's about time</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or post-infarction complications. The horizontal time axis proposes duration of therapies and timeframes for pharmacotherapeutic re-assessment, and should be responsive to the temporal evolution of post-MI risk and events. ADP, adenosine diphosphate receptor inhibitors; ASA, acetylsalicylic acid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trials; TG, triglyceride. *Pending guideline recommendations.</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLAzEUhYMotlb_gAvJTjdj886MrkrxBQU3Cu5CJr1xps50apJB_PeO9LG6cDnn4_AhdEnJLSUFn0IfKrAhraZQWUsJ50doTCVjWaGEPEZjQguZKZV_jNBZjCtCSK6oOkUjzgXLNcnH6H4xENb1-hP_VJAqCDh1OPZlCtYlXEKyWdl07gtCvMN1uo7Yll2fcKpbOEcn3jYRLnZ3gt4fH97mz9ni9ellPltkjgudMq0LopSXnjAnxTAPSu-1kMQJTnKnvBvmDH-prVDOLrl0VoEUVumlcNzyCbrZcjeh--4hJtPW0UHT2DV0fTRMaM0UzSUfomwbdaGLMYA3m1C3NvwaSsy_NHOQZvbShtLVjt-XLSwPlb0l_gcQimr7</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>van Diepen, Sean</creator><creator>Armstrong, Paul W</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0460-3445</orcidid></search><sort><creationdate>20210301</creationdate><title>Learning whether to subtract beta-blockers: it's about time</title><author>van Diepen, Sean ; Armstrong, Paul W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-779066f5f02c54522ebff7450c4308c6fc33445257a46cad35ca6e54a67d4c3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Diepen, Sean</creatorcontrib><creatorcontrib>Armstrong, Paul W</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Diepen, Sean</au><au>Armstrong, Paul W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Learning whether to subtract beta-blockers: it's about time</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>42</volume><issue>9</issue><spage>915</spage><epage>918</epage><pages>915-918</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Proposed framework for foundational and provisional secondary prevention therapy over time in low-risk post-MI patients. Foundational therapies should be considered in all patients without contraindications, while provisional therapies should be considered in selected patients with comorbidities or post-infarction complications. The horizontal time axis proposes duration of therapies and timeframes for pharmacotherapeutic re-assessment, and should be responsive to the temporal evolution of post-MI risk and events. ADP, adenosine diphosphate receptor inhibitors; ASA, acetylsalicylic acid; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trials; TG, triglyceride. *Pending guideline recommendations.</abstract><cop>England</cop><pmid>33428708</pmid><doi>10.1093/eurheartj/ehaa1033</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0460-3445</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2021-03, Vol.42 (9), p.915-918
issn 0195-668X
1522-9645
language eng
recordid cdi_proquest_miscellaneous_2477261853
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Learning whether to subtract beta-blockers: it's about time
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A34%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Learning%20whether%20to%20subtract%20beta-blockers:%20it's%20about%20time&rft.jtitle=European%20heart%20journal&rft.au=van%20Diepen,%20Sean&rft.date=2021-03-01&rft.volume=42&rft.issue=9&rft.spage=915&rft.epage=918&rft.pages=915-918&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehaa1033&rft_dat=%3Cproquest_cross%3E2477261853%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2477261853&rft_id=info:pmid/33428708&rfr_iscdi=true